SCHEMBL23142246

SCHEMBL23142246

Cc1cc2c(s1)C(=O)NCCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.42
MAPKAPK2 P49137 2/20 0.42
ALDH1A1 P00352 4/20 0.39
PNMT P11086 1/20 0.39
TSHR P16473 2/20 0.37
PARP10 Q53GL7 2/20 0.37
PARP11 Q9NR21 1/20 0.37
PARP1 P09874 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
ALOX12 P18054 2/20 0.36
ATM Q13315 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13361329 0.89 PARP10 (0.46) CDK1MAPKAPK2PNMTTSHRPARP10
SCHEMBL23177730 0.79 CDK1 (0.39) CDK1MAPKAPK2ALDH1A1TSHRPARP10
SCHEMBL24733658 0.79 CDK1 (0.39) CDK1MAPKAPK2ALDH1A1TSHRPARP10
SCHEMBL12240927 0.78 PNMT (0.39) PNMTTSHRPARP10PARP11PARP1
SCHEMBL17970192 0.74 MEN1 (0.36) ALDH1A1PNMTTSHRTDP1MEN1
SCHEMBL13303499 0.74 MEN1 (0.40) ALDH1A1PNMTTSHRMEN1CYP2C19
SCHEMBL8918437 0.73 ALDH1A1 (0.35) CDK1MAPKAPK2ALDH1A1TSHRTDP1
SCHEMBL8917048 0.72 MEN1 (0.46) CDK1MAPKAPK2ALDH1A1PNMTTSHR
SCHEMBL8915748 0.71 GSK3B (0.43) CDK1MAPKAPK2ALDH1A1TSHRTDP1
SCHEMBL13963484 0.70 PNMT (0.43) ALDH1A1PNMTTSHRTDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12157726-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof SHANGHAI ZHIMENG BIOPHARMA INC. 2024-12-03 US disclosed
EP-3798220-B1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC (CN) 2023-08-23 EP disclosed
EP-3798220-B1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC (CN) 2023-08-23 EP disclosed
US-20220227721-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2022-07-21 US disclosed
US-11365181-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2022-06-21 US disclosed
US-11365181-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2022-06-21 US disclosed
CN-110511220-B P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine 上海挚盟医药科技有限公司 2022-04-01 CN disclosed
US-20210163429-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2021-06-03 US disclosed
US-20210163429-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF SHANGHAI ZHIMENG BIOPHARMA INC. (CN) 2021-06-03 US disclosed
EP-3798220-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF Shanghai Zhimeng Biopharma, Inc. (CN) 2021-03-31 EP disclosed
EP-3798220-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF Shanghai Zhimeng Biopharma, Inc. (CN) 2021-03-31 EP disclosed
CN-112119079-A P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine 上海挚盟医药科技有限公司 2020-12-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157726-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof KCNJ2, KCNN2, KCNH2 CDK1 4214/4885MAPKAPK2 213/4885ALDH1A1 1733/4885
US-20220227721-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF KCNJ2, KCNN2, KCNH2 CDK1 4214/4885MAPKAPK2 213/4885ALDH1A1 1733/4885
US-11365181-B2 P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof KCNJ2, KCNN2, KCNH2 CDK1 4157/4885MAPKAPK2 209/4885ALDH1A1 1705/4885
US-20210163429-A1 P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF KCNJ2, KCNN2, KCNH2 CDK1 4157/4885MAPKAPK2 209/4885ALDH1A1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.